LISA GRIFFIN: Open Payments
NPI 1609273002 · ABBEVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$883 in 40 payments from 14 companies in 2025. Trend: 2023 $319 · 2024 $702 · 2025 $883
Food & beverage: $883
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 7 | $194 |
| Otsuka America Pharmaceutical, Inc. | 9 | $177 |
| Braeburn Inc. | 5 | $93 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| EMD Serono, Inc. | 2 | $62 |
| Merck Sharp & Dohme LLC | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| ABBVIE INC. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
Products named: ARISTADA, BRIXADI, REXULTI, Auvelity, FANAPT, VRAYLAR, ABILIFY MAINTENA, PIFELTRO.
Industry payments across LA — which companies pay providers there.
